Placental oxidative stress plays a key role in the pathophysiology of several placenta-related disorders including intrauterine growth restriction.
INTRODUCTION
Oxidative stress occurs when cellular production of reactive oxygen species (ROS), by-products of cellular respiration, exceeds the capacity of local antioxidant defenses and thus damages DNA, lipids, and proteins [1] . Placental ROS generation is high because of the high metabolic activity of placental cells [2] , and placental oxidative stress is a prominent feature of several pregnancy disorders, including gestational diabetes, preeclampsia, and idiopathic intrauterine growth restriction [3] [4] [5] [6] [7] . The importance of limiting placental oxidative stress was recently shown in a study where overexpression of the antioxidant thioredoxin-1 reduced placental oxidative damage and enhanced fetal growth in the mouse [8] . This suggests that during normal pregnancy placental ROS may tonically suppress fetal growth.
Fatty acids are important biological constituents that serve structural, energetic, and signaling roles [9] and as such can affect cellular ROS levels [10, 11] . The developing fetus requires substantial amounts of fatty acids to support rapid cellular growth and activity, and among these the omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) are crucial [12] . The most biologically important n-3 and n-6 PUFAs are eicosapentaenoic acid (EPA; 20:5n-3), docosahexaenoic acid (DHA; 22:6n-3), dihomogammalinolenic acid (20:3n-6), and arachidonic acid (AA; 20:4n-6) [12] . While these PUFAs are metabolic derivatives of the essential fatty acids a-linolenic acid and linoleic acid, their formation from these precursors is energetically demanding and so they are most readily obtained directly from the diet [13] . All n-3 and n-6 PUFAs acquired by the fetus are derived from maternal dietary intake and metabolism [14] , but the precise molecular mechanisms that regulate fatty acid delivery from maternal to fetal circulations remain poorly understood [15] . Comparisons between maternal and fetal plasma fatty acid levels, however, demonstrate that directional and preferential transfer occurs, and this closely correlates with fetal requirement [12, 16] . This suggests that the placenta is capable of selective transfer of required fatty acids from the maternal supply [14] .
Both n-3 and n-6 PUFAs are critical for overall fetal development, and although subject to some controversy, maternal dietary supplementation with n-3 PUFAs may be beneficial to pregnancy outcome. For example, increased maternal dietary intake of n-3 PUFAs in human pregnancy increases gestation length [17] , may reduce the risk of pregnancy complications [18] [19] [20] , and increases fetal growth [21] . Potentially, such effects could be mediated via a reduced oxidative burden within the placenta because n-3 PUFAs reduce ROS generation in vitro [10, 11] and dietary n-3 PUFA supplementation reduces plasma and urinary F 2 -isoprostanes, reliable markers of in vivo oxidative stress [22] . In contrast, however, n-3 PUFA supplementation has been shown to enhance free radical production and associated cellular damage, most notably in the uterus and liver [23] [24] [25] . As such, it is important to ascertain the potential benefits and risks associated with n-3 PUFA supplementation during pregnancy because many women currently increase n-3 PUFA intake during gestation and the majority of them will experience uncomplicated pregnancies.
In this study, we examined the impact of increased maternal dietary intake of n-3 PUFAs on the placental and fetal lipid environments and placental oxidative stress in rat pregnancy. Measurements were made on Days 17 and 22 of gestation (term ¼ Day 23), thus covering the major period of fetal growth.
MATERIALS AND METHODS

Animals
Nulliparous albino Wistar rats, 8-to 12-wk old, were obtained from the Animal Resources Centre (Murdoch, Australia) and maintained under controlled conditions as described previously [26] . Rats were mated overnight, with Day 1 of pregnancy designated as the day on which spermatozoa were present in a vaginal smear. On Day 1 of pregnancy, mothers were placed on either a standard (Std) or high n-3 PUFA (Hn3) isocaloric semipure diet (Specialty Feeds, Glen Forrest, Australia). Both diets consisted of 5% total fat; the detailed fatty acid composition of the diets is shown in Table 1 . Maternal weight and food intake were recorded daily. All the procedures involving animals were conducted after approval by the Animal Ethics Committee of The University of Western Australia.
Tissue Collection
Rats were anesthetized with isofluorane/nitrous oxide at either Day 17 or 22 of gestation. Three fetus-placenta pairs were obtained from the midregion of each uterine horn (total of six per mother) and weighed. Each placenta was then dissected into junctional (JZ) and labyrinth (LZ) zones, which were weighed individually and snap frozen in liquid nitrogen. Effective separation of placental zones by this method has been confirmed by differential gene expression [26] . Whole fetuses were collected at Day 17 of gestation, fetal livers were collected at Day 22, and a portion of maternal liver was collected at both days. A blood sample obtained from the dorsal aorta was mixed with 10:1 (vol:vol) 0.6 M ethylenediaminetetraacetic acid (EDTA) and centrifuged at 13 000 3 g for 6 min to obtain plasma. All the tissue and plasma samples were snap frozen in liquid nitrogen and stored at À808C until further analysis.
Fetal Sex Determination
Fetal sex was determined by measuring anogenital distance in Day 22 fetuses [27] and at Day 17 by PCR amplification of the SRY gene. Briefly, ;15 mg of Day 17 fetal tail tissue was digested in 500 ll digestion buffer (50 mM Tris-HCl, pH 8, 100 mM EDTA, 100 mM NaCl, 1 % SDS) and 0.5 mg proteinase K (Promega, Sydney, Australia). Samples were incubated at 558C for 3 h, and 180 ll of 4 M NaCl was added, then centrifuged at 13 000 3 g for 10 min. Genomic DNA was precipitated in isopropanol, washed in 70% ethanol, and resuspended in double distilled H 2 O. The concentration and purity of genomic DNA was determined by measurement of absorbance at 260 and 280 nm (A260/A280 ' 1.8) using the Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE). Analysis of the presence of genomic SRY was performed by real-time PCR on the Rotorgene 6000 (Corbett Industries, Sydney, Australia) using iQSYBR Green Supermix (BioRad, Hercules, CA). Primer pairs for the Sry1 gene (F: GAGAGAGGCA CAAGTTGGC; R: GCCTCCTGGAAAAAGGGCC) were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast) [28] . Male samples amplified the product by 25 cycles.
Measurement of F 2 -Isoprostanes
Placental tissues (;50 mg) were ground to a fine powder with a porcelain mortar and pestle chilled with liquid nitrogen. F 2 -isoprostanes were extracted and then measured in duplicate by gas chromatography-mass spectrometry using electron capture chemical ionization as previously described [29] .
Measurement of Fatty Acid Composition
Tissue samples (maternal liver, LZ, JZ, Day 17 whole fetus, Day 22 fetal liver; 40-60 mg) were ground to a fine powder with a porcelain mortar and pestle chilled with liquid nitrogen. Tissue and plasma samples were extracted with 2 ml chloroform/methanol (2:1 vol:vol). Fatty acid methyl esters were prepared by treatment of total lipid extracts with 4% H 2 SO 4 in methanol at 908C for 20 min and analyzed by gas liquid chromatography using an Agilent Technologies model 7890A gas chromatograph (Santa Clara, CA). The column was a 100 m 3 0.25 mm 3 0.20 lm Supelco SP-2560 (Bellefonte, PA) with a temperature program as follows: 1808C (1.75 min), then 58C/min to 2008C (held 1.75 min), and then 108C/min to 2408C (held 4.5 min) using hydrogen as the carrier gas at a split ratio of 30:1. Peaks were identified by comparison with a known standard mixture.
Statistical Analysis
All the analyses were conducted using Genstat version 14 (VSN International Ltd., Hemel Hempstead, U.K.). Where the data were not normally distributed (based on residual plot analyses), values were log-transformed prior to statistical analysis. Variations in maternal weight gain and food intake were assessed by repeated-measure ANOVA. Fetal, whole placental, and placental zone weight values for each pregnancy were calculated as the average of the six estimates of each, and three-way ANOVA was used to compare weights with variation attributed to maternal diet, gestational age, and fetal sex. Litter averages of fetal/placental and fetal/LZ weight ratios were similarly analyzed. In every instance, n refers to the number of litters analyzed. Variation in F 2 -isoprostane concentrations and fatty acid compositions were assessed by fourway and/or three-way ANOVA, where appropriate, with variation attributed to maternal diet, gestational age, placental zone, and fetal sex. When significant interaction between sources of variation was seen, separate comparisons were conducted by three-way or two-way ANOVA as appropriate. For all the ANOVAs, where the F test reached statistical significance (P , 0.05), subsequent post hoc analyses were performed using least significant difference (LSD) tests [30] . Relationships between fatty acid levels in tissues and plasma were first assessed by linear regression analysis [30] . The slope and elevation of regression lines were subsequently compared between diet groups by analysis of covariance (ANCOVA) [30] .
RESULTS
Pregnancy Outcome
Maternal weights at Days 1, 17, and 22 of gestation, maternal caloric intake across gestation (data not shown), litter sizes, and resorption rates (Table 2) were similar in the two diet groups. Dietary intake of total n-3 PUFAs was 1.40 6 0.04 mg/kg body weight per day for the Std group, and 61.5 6 1.6 mg/kg body weight per day for the Hn3 group (P , 0.001). Fetal, placental, and zonal weights varied with gestational day as did fetal/placental and fetal/LZ weight ratios (all P , 0.01; Table 2 ). There was significant interaction between gestational age and diet for fetal, placental, and LZ weights (each P , 0.01), and subsequent analysis by two-way ANOVA (diet and fetal sex) showed significant diet (but not sex) effects for each at Day 22. Specifically, fetal weight (5.8%, P , 0.05) and placental weight (12.0%, P , 0.05) were both elevated in the Hn3 group (combined data for males and females; Table 2 ). The enhanced placental growth at Day 22 was largely due to the LZ (13.5% weight increase, P , 0.01; Table 2 ) with no significant change in JZ weight. Interestingly, the sum of JZ and LZ weights was always slightly less than the corresponding total placental weight, possibly due to fluid loss during the dissection procedure. Thus, even though cross-contamination between the two placental zones is very unlikely [26] , the dissection procedure per se is a likely additional source of variation. Ratios between fetal, whole placenta, and LZ weights were not significantly different ( Table 2) , indicative of comparable placental efficiency between diet groups.
Placental F 2 -Isoprostanes
Levels of F 2 -isoprostanes were higher in female than male placentas overall (P , 0.01), but both sexes showed similar gestational age, zonal, and dietary effects (Fig. 1) . Specifically, levels of F 2 -isoprostanes were greater in placental JZ than LZ at Day 17 (1.3-fold, P , 0.001) and Day 22 (8.7-fold, P , 0.001; Fig. 1 ). Moreover, while F 2 -isoprostanes fell in the LZ between Days 17 and 22 (50%; P , 0.001), they increased markedly in the JZ over the same period (3-fold; P , 0.001). The maternal Hn3 diet reduced F 2 -isoprostanes in the LZ on both days (by 31% at Day 17, P , 0.05; by 11% at Day 22, P , 0.05), but in the JZ, this decrease was evident only at Day 22 (29% lower, P , 0.05; Fig. 1 ).
Plasma and Tissue Fatty Acid Profiles
Detailed fatty acid profiles for plasma and tissues are shown in Supplemental Tables S1-S4 (all the Supplemental Data are available online at www.biolreprod.org). Maternal plasma levels of EPA, DHA, and total n-3 PUFAs (% of total fatty acids) were all elevated (overall effect for each P , 0.001, ANOVA) in the Hn3 group at Days 17 and 22 (Fig. 2) . Maternal plasma levels of total saturated fatty acids were also elevated slightly in the Hn3 group at Day 17 (13.4%, P , 0.05; Fig. 2 ) but not at Day 22. In contrast, plasma levels of AA were reduced in the Hn3 group (Day 17: 29% lower; Day 22: 40% lower; P , 0.001), as were total n-6 PUFA levels (27% and 41% lower, respectively, P , 0.001; Fig. 2) .
Fetal sex did not affect the PUFA composition of the fetal or placental tissues (Supplemental Tables S2-S4) , and so male and female samples were pooled for further analyses. Consistent with maternal plasma profiles, consumption of the Hn3 diet increased total n-3 PUFAs and reduced total n-6 PUFAs in all the tissues examined (P , 0.001; Figs. 3 and 4) . The single exception in this regard was the JZ at Day 22, which exhibited a marked decrease of all PUFAs (P , 0.001; Fig. 3b) . Interestingly, the Hn3 diet slightly increased total saturated fatty acid levels in maternal liver (at Day 17), placental zones (both days), whole fetus (Day 17) (all P , 0.05; see Supplemental Tables S1-S4), and fetal liver (Day 22; P , 0.001; Fig. 4 ). . Overall, females had higher levels of F 2 -isoprostanes than males (P , 0.01), and JZ levels were higher than LZ (P , 0.001). *P , 0.05, **P , 0.01 overall compared to corresponding Std diet group in the same zone (two-way ANOVA; post hoc LSD); §P , 0.001 compared to Day 17 in the same zone (two-way ANOVA).
n-3 FATTY ACIDS AND PLACENTAL OXIDATIVE STATUS
Relationships among Fatty Acid Profiles of Maternal Plasma and Various Tissues
Diet-induced changes in tissue fatty acid profiles (maternal liver, placental LZ and JZ, whole fetus, and fetal liver) all broadly paralleled those in maternal plasma for individual fatty acids and for fatty acid groups (Supplemental Table S5 ). For example, regression analysis showed that total n-3 PUFA composition in maternal plasma was positively correlated (P , 0.001) with that in maternal liver (Fig. 5, a and b ) and in LZ (Fig. 5, c and d) on both gestational days, and in each case the slope of the regression lines was similar between the diet groups. Interestingly, however, the elevation of the regression lines for the maternal liver (Day 17) and for LZ (both days) was higher in the Hn3 group (P , 0.05, ANCOVA; Fig. 5 and Supplemental Table S6 ), indicating that levels of n-3 PUFAs in these tissues were proportionally higher than would be predicted on the basis of the observed association in the Std group. Similar observations were made for the relationship between total n-3 PUFAs in maternal plasma and JZ at Day 17, but by Day 22, these were lost as a result of the striking reduction in the levels of all PUFAs in this placental zone.
Consistent with the maternal-fetal transport role of the placental LZ, fatty acid profiles in this zone were strongly correlated with those in the whole fetus (Day 17) and in fetal liver (Day 22; Fig. 6a ). These observations, together with the positive association between total PUFA subgroups in maternal plasma and LZ described above, would suggest a similar association exists between maternal plasma profiles and those in the whole fetus (Day 17) and fetal liver (Day 22). Indeed, this was clearly evident for total n-3 PUFAs at Days 17 and 22 ( Fig. 6b) as well as for individual fatty acids (EPA, DHA, and AA) and total n-6 PUFAs (Supplemental Table S5 ). Collectively, these data indicate that maternal plasma PUFA profiles are strongly predictive of the corresponding profiles in placental and fetal tissues. 
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DISCUSSION
The present study examined the impact of maternal dietary supplementation with n-3 PUFAs on the placental oxidative burden in otherwise normal pregnancy. We have shown that n-3 PUFA supplementation reduced oxidative stress in both placental zones and that this was accompanied by enhanced growth of the placental LZ and the fetus.
Oxidative stress occurs when intracellular levels of ROS accumulate as a result of either enhanced production (e.g., after ischemia-reperfusion injury) and/or when antioxidant processes are compromised. The resultant damage to cellular protein, lipid, and DNA promotes cellular dysfunction and can thereby lead to pathological outcomes. In this regard, F 2 -isoprostanes are considered the most reliable markers of in vivo lipid peroxidation [31] . Placental oxidative stress is now recognized as a key feature of several placental pathologies in which fetal growth can be compromised, including preeclampsia [32] , and so the potential for n-3 PUFA supplementation to limit the oxidative burden of the placenta could be therapeutically important. On the other hand, n-3 PUFAs are susceptible to lipid peroxidation and so could potentially enhance tissue damage [1] . The current study shows no such adverse effect of dietary n-3 PUFAs as evidenced by the decline in lipid peroxidation (F 2 -isoprostanes) with the Hn3 diet. While recognizing the potential benefits of n-3 PUFA intake during pregnancy, the World Health Organization states that evidence is insufficient to support routine supplementation during normal pregnancy [33] . Nevertheless, it has been advised that adequate consumption of n-3 PUFAs for pregnant women is around 2.7 g/day [34] , equivalent to 37 mg/kg body weight per day (based on average adult female weight in the United States [35] ). In the current study, even though total n-3 PUFA intake with Hn3 diet (62 mg/kg body weight per day) exceeded the suggested adequate level for human pregnancy, placental lipid peroxidation was still reduced by as much as 30% (depending on placental zone and gestational age). 
n-3 FATTY ACIDS AND PLACENTAL OXIDATIVE STATUS
The placental LZ is the major site of maternal-fetal transfer and undergoes rapid growth over the final week of gestation to support the growing fetus. Our observation that the enhanced placental growth in n-3 PUFA-supplemented pregnancies occurred primarily in the LZ is consistent with the associated increase in fetal growth. Moreover, n-3 PUFA enrichment reduced levels of F 2 -isoprostanes in the LZ on Days 17 and 22, indicative of reduced oxidative stress. This reduced oxidative burden presumably contributed to enhanced fetal growth, an observation consistent with that of Umekawa et al. [8] who demonstrated that global overexpression of thioredoxin-1 in mouse pregnancy reduced placental oxidative status and increased fetal growth.
This study also shows that levels of F 2 -isoprostanes in the LZ are reduced during late gestation, regardless of maternal diet, suggestive of either lower ROS production or increased antioxidant capacity. The latter is more plausible given the likely increase in LZ metabolic activity to support the rapidly growing fetus over this period [36] . Indeed, we recently reported that LZ expression of the superoxide dismutases Sod1 and Sod2 genes both increase toward term as does LZ expression of thioredoxin-1 [37] . In contrast to the LZ, F 2 -isoprostane levels in the adjacent JZ increased markedly between Days 17 and 22 of gestation, a period of relatively little growth in this zone. We have previously shown that the JZ has higher rates of basal and glucocorticoid-induced apoptosis compared with the LZ at term [38] , and so increased oxidative stress may relate to regression of the JZ in late gestation. The increase in JZ lipid peroxidation may also be linked to the concomitant, marked decline in JZ PUFA levels.
In addition to their antioxidative effects, n-3 PUFAs influence a number of signaling pathways that may have contributed to the enhanced placental and fetal growth. PUFAs are natural ligands for the peroxisome proliferator-activated receptors (PPARs), transcription factors involved in gene regulation of metabolic, anti-inflammatory and developmental processes [39] . While all three PPARs (a, b, and c) are present in the placenta [40] , PPARc is directly involved in trophoblastic differentiation and labyrinthine vascularization [39] . We have previously shown that glucocorticoid-induced fetal growth restriction in the rat is associated with reduced LZ expression of PPARc and placental vascularity [40] . It will be of interest to examine whether increased vascularity accompanies enhanced placental growth in the n-3 PUFA supplemented pregnancies.
The anti-inflammatory and proresolving properties of n-3 PUFAs are also well characterized, with effects on eicosanoid synthesis, resolvin and protectin production, NF-jB activation, and inflammatory cytokine production [9] . Increased inflammation in pathological pregnancies has been linked to restriction of fetal and placental growth [41] , and normal pregnancy is considered a state of mild, systemic inflammation [42] . Therefore, the current findings raise the possibility that n-3 PUFA supplementation and the associated increase in n-3 PUFA levels in the placenta may promote fetal growth by limiting placental inflammation.
Although the Std and Hn3 diets differed markedly in n-3 PUFA composition, they provided similar levels of total PUFAs. Moreover, the two diets contained comparable levels of saturated fats, which is important given their potentially adverse effects on various aspects of normal physiology [43] . Accordingly, total PUFAs and saturated fats in maternal plasma and liver were similar in the two diet groups at both stages of gestation. Although maternal plasma AA levels were slightly lower in the Hn3 group, this effect was much less than that previously described following fish oil supplementation [44] . In this previous study it was proposed that reduced AA levels likely reflected inhibition of its synthesis from linoleic acid as a result of competitive inhibition of D6-desaturase by n-3 PUFAs [44] . It is plausible that the attenuated AA reduction in the Hn3 group observed in the present study was due to the higher levels of AA in our Hn3 semipure diet (see Table 1 ).
Our data confirm that maternal (plasma and liver), placental, and fetal fatty acid composition are each highly dependent on maternal dietary intake of fatty acids. Moreover, linear regression analyses showed strong positive associations between maternal plasma fatty acid profiles and those in each of the various maternal, placental, and fetal tissues, consistent with previous findings [44] . The present study extends this previous work by characterizing the relationships between fatty acid levels in maternal plasma and the various tissues. Overall, diet-induced changes in maternal plasma fatty acids predicted changes in maternal liver and placental LZ, and this was evident for individual fatty acids and fatty acid groups (total n-3 and n-6 PUFAs). Tissue levels of n-3 PUFAs, however, were proportionally higher in the Hn3 group than would be predicted simply on the basis of maternal plasma levels in the Std group. This suggests that in the n-3 PUFA-supplemented pregnancies, tissue uptake and retention of n-3 PUFAs is enhanced relative to plasma levels, although it remains uncertain whether this provides any particular physiological benefit. Moreover, these high levels of n-3 PUFAs in the placental LZ are consistent with previous reports showing that the human placenta preferentially transports DHA from the maternal to fetal circulation [45] .
Fatty acid composition of the JZ correlated with maternal circulating levels at Day 17, but by Day 22, this placental zone exhibited a drastic reduction in the levels of all PUFAs. As this effect was only observed at gestational Day 22 and also coincided with the zone-specific elevation in lipid peroxidation, it may reflect the regressive nature of the JZ near term [38] . The depletion of PUFAs and exacerbated oxidative status of the late gestation JZ further highlights the need to consider JZ and LZ tissues independently in rodent studies.
In conclusion, this study demonstrates that maternal dietary supplementation with n-3 PUFAs reduces placental oxidative status and increases fetal and placental growth. Moreover, maternal fatty acid intake directly influences placental and fetal fatty acid composition, highlighting the potential of n-3 PUFA dietary supplementation to favorably modify the placental lipid environment and alleviate the oxidative burden of the placenta.
